Nephros Inc (NEPH) stock
NEPHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3020% below fair value
$3.31+0.24 (+7.82%)
Close on Nov 12, 2026Market cap $35.95MP/E 18.4Yield –
Nephros r&d expenses
Research and development expenses are spending on new products and technology.
Nephros's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.44M, up 20.2% year over year. For fiscal 2025 it was $1.34M, up 47.8% from the year before. Over ten years it grew 4.9% a year on average. The highest annual figure on record is $3.09M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.34M | +47.8% |
| FY2024 | Dec 31, 2024 | $906.00K | +3.8% |
| FY2023 | Dec 31, 2023 | $873.00K | -30.4% |
| FY2022 | Dec 31, 2022 | $1.26M | -16.2% |
| FY2021 | Dec 31, 2021 | $1.50M | -45.7% |
| FY2020 | Dec 31, 2020 | $2.76M | -10.7% |
| FY2019 | Dec 31, 2019 | $3.09M | +100.8% |
| FY2018 | Dec 31, 2018 | $1.54M | +53.6% |
| FY2017 | Dec 31, 2017 | $1.00M | -7.1% |
| FY2016 | Dec 31, 2016 | $1.08M | +30.6% |
| FY2015 | Dec 31, 2015 | $826.00K | +5.8% |
| FY2014 | Dec 31, 2014 | $781.00K | -9.9% |
| FY2013 | Dec 31, 2013 | $867.00K | +37.2% |
| FY2012 | Dec 31, 2012 | $632.00K | +40.1% |
| FY2011 | Dec 31, 2011 | $451.00K | +24.6% |
| FY2010 | Dec 31, 2010 | $362.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $331.00K | -2.1% |
| Q2 FY2026 | Jun 30, 2026 | $366.00K | +17.7% |
| Q1 FY2026 | Mar 31, 2026 | $346.00K | +17.3% |
| Q4 FY2025 | Dec 31, 2025 | $395.00K | +56.7% |
| Q3 FY2025 | Sep 30, 2025 | $338.00K | +79.8% |
| Q2 FY2025 | Jun 30, 2025 | $311.00K | +22.4% |
| Q1 FY2025 | Mar 31, 2025 | $295.00K | +39.2% |
| Q4 FY2024 | Dec 31, 2024 | $252.00K | +21.2% |
| Q3 FY2024 | Sep 30, 2024 | $188.00K | -8.3% |
| Q2 FY2024 | Jun 30, 2024 | $254.00K | +14.9% |
| Q1 FY2024 | Mar 31, 2024 | $212.00K | -11.3% |
| Q4 FY2023 | Dec 31, 2023 | $208.00K | -42.1% |
| Q3 FY2023 | Sep 30, 2023 | $205.00K | -18.7% |
| Q2 FY2023 | Jun 30, 2023 | $221.00K | -19.0% |
| Q1 FY2023 | Mar 31, 2023 | $239.00K | -35.8% |
| Q4 FY2022 | Dec 31, 2022 | $359.00K | +9.5% |
| Q3 FY2022 | Sep 30, 2022 | $252.00K | -36.2% |
| Q2 FY2022 | Jun 30, 2022 | $273.00K | -43.9% |
| Q1 FY2022 | Mar 31, 2022 | $372.00K | -33.1% |
| Q4 FY2021 | Dec 31, 2021 | $328.00K | -46.1% |
| Q3 FY2021 | Sep 30, 2021 | $395.00K | -47.4% |
| Q2 FY2021 | Jun 30, 2021 | $487.00K | -41.7% |
| Q1 FY2021 | Mar 31, 2021 | $556.00K | -1.2% |
| Q4 FY2020 | Dec 31, 2020 | $609.00K | -20.3% |
| Q3 FY2020 | Sep 30, 2020 | $751.00K | -3.3% |
| Q2 FY2020 | Jun 30, 2020 | $836.00K | +5.4% |
| Q1 FY2020 | Mar 31, 2020 | $563.00K | -25.5% |
| Q4 FY2019 | Dec 31, 2019 | $764.00K | +39.9% |
| Q3 FY2019 | Sep 30, 2019 | $777.00K | +120.7% |
| Q2 FY2019 | Jun 30, 2019 | $793.00K | +125.3% |
| Q1 FY2019 | Mar 31, 2019 | $756.00K | +161.6% |
| Q4 FY2018 | Dec 31, 2018 | $546.00K | +111.6% |
| Q3 FY2018 | Sep 30, 2018 | $352.00K | +48.5% |
| Q2 FY2018 | Jun 30, 2018 | $352.00K | +27.1% |
| Q1 FY2018 | Mar 31, 2018 | $289.00K | +25.1% |
| Q4 FY2017 | Dec 31, 2017 | $258.00K | -18.4% |
| Q3 FY2017 | Sep 30, 2017 | $237.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $277.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $231.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $316.00K | – |
See a number that looks wrong?